Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759201 | 0.82 | CA2 (0.43) | CA1CA2ENPP2TTRKDM4E | |
| SCHEMBL20968620 | 0.78 | CA2 (0.34) | CA1CA2ENPP2TTRKDM4E | |
| SCHEMBL266510 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL4027923 | 0.74 | ADRA2A (0.42) | STSCA1CA2ENPP2TTR | |
| SCHEMBL442154 | 0.74 | ALDH1A1 (0.45) | CA1CA2ENPP2TTR | |
| SCHEMBL29956883 | 0.74 | ALDH1A1 (0.45) | CA1CA2ENPP2TTR | |
| SCHEMBL28586692 | 0.72 | PBRM1 (0.58) | CYP2A6CA1CA2ENPP2PBRM1 | |
| SCHEMBL1891425 | 0.72 | CASP1 (0.53) | CYP1A2CYP11B1CYP11B2PBRM1 | |
| SCHEMBL3101723 | 0.71 | NPC1 (0.42) | CA1CA2ENPP2TTRKDM4E | |
| SCHEMBL1701852 | 0.71 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371410-A1 | PROCESS FOR PREPARING ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2021-12-02 | — | — | US | disclosed |
| US-20200140427-A1 | A PROCESS FOR PREPARING ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140427-A1 | A PROCESS FOR PREPARING ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PLEC, FCGR3B, SF3B5 | CYP2A6 741/4885CYP1A2 1474/4885CYP3A4 232/4885 |
| US-20210371410-A1 | PROCESS FOR PREPARING ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PLEC, SF3B5, FCGR3B | CYP2A6 612/4885CYP1A2 1390/4885CYP3A4 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.